CONMED Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
- Sales increased by 30.4% in the fourth quarter of 2023 compared to the previous year.
- Domestic revenue saw a significant increase of 33.3% year over year.
- Adjusted diluted net earnings per share for the fourth quarter of 2023 increased by 152.4% compared to the same period in 2022.
- The company expects continued growth in 2024, with projected revenue and earnings per share growth.
- None.
Insights
The reported sales growth of 30.4% year over year and a significant increase in adjusted diluted net earnings per share by 152.4% for Q4 2023 and a 19.1% sales growth for the full year, are indicative of a robust financial performance by CONMED Corporation. This is particularly noteworthy in the context of an industry where single-digit growth rates are more common. The company's ability to outperform industry norms may be attributed to successful product launches, strategic acquisitions, or increased market penetration.
CONMED's expectation of 8% to 10% revenue growth for 2024 suggests a confident outlook, although it represents a deceleration from the 2023 growth rate. This projected slowdown could be due to market saturation, increased competition, or the cyclical nature of the industry. Investors should consider the potential for reversion to mean growth rates when evaluating the company's future performance. Furthermore, the forecasted 25% to 28% growth in adjusted diluted net earnings per share for 2024 reflects an optimistic earnings leverage, likely due to operational efficiencies and cost management strategies.
CONMED's impressive growth in both domestic (33.3%) and international (26.5%) markets underscores the company's successful expansion and penetration strategies. The consistent growth across the General Surgery and Orthopedics categories suggests a well-diversified portfolio that mitigates reliance on any single product line. This diversification is a strategic advantage in the medical technology industry, where demand can fluctuate based on procedural volumes and healthcare spending.
The mention of immaterial impact from foreign currency exchange rates in 2024 implies effective financial hedging strategies or a natural hedge through a balanced global revenue mix. Companies that can minimize the impact of currency fluctuations are better positioned to maintain stable profit margins, an important consideration for investors concerned about international market exposure.
The strong performance in both single-use products (28.1% growth) and capital products (42.9% growth) indicates a healthy demand for CONMED's offerings. Single-use products are essential in ensuring compliance with hygiene standards, while capital products often represent long-term investments by healthcare providers. The ability to grow both segments suggests that CONMED is effectively addressing the needs of its customer base.
Acquisitions contributing approximately 250 basis points of growth highlight the company's strategic use of M&A to fuel expansion. This is a common growth strategy in the medical device industry, allowing companies to rapidly acquire new technologies and expand their product portfolios. However, it is crucial for investors to monitor how these acquisitions are integrated and whether they lead to sustained growth or if they pose risks due to integration challenges.
Fourth Quarter 2023 Highlights
-
Sales of
$327.0 million 30.4% year over year as reported and31.5% in constant currency -
Domestic revenue increased
33.3% year over year. -
International revenue increased
26.5% year over year as reported and29.0% in constant currency. -
Diluted net earnings per share (GAAP) were
$1.05 $0.86 -
Adjusted diluted net earnings per share(1) were
$1.06 152.4% compared to the fourth quarter of 2022.
Full-Year 2023 Highlights
-
Sales of
$1,244.7 million 19.1% year over year as reported and20.9% in constant currency. Acquisitions contributed approximately 250 basis points of growth. -
Domestic revenue increased
20.9% year over year. -
International revenue increased
16.7% year over year as reported and20.9% in constant currency. -
Diluted net earnings per share (GAAP) were
$2.04 $2.68 -
Adjusted diluted net earnings per share(1) were
$3.45 30.2% compared to 2022.
“2023 was a great year for CONMED, and I am proud that our global business delivered record revenue in both the fourth quarter and for the full year,” commented Curt R. Hartman, CONMED’s Chair of the Board, President, and Chief Executive Officer. “The balanced growth we saw across our various businesses and geographies is a testament to the strength of the portfolio that we have built. As we shift our focus to 2024, we are very excited to continue delivering innovative technology solutions to our customers and patients across both the General Surgery and Orthopedics categories.”
2024 Outlook
The Company expects full-year 2024 reported revenue between
The Company expects full-year 2024 adjusted diluted net earnings per share(2) in the range of
The impact of foreign currency exchange rates in 2024 is expected to be immaterial.
Supplemental Financial Disclosures
(1) A reconciliation of reported diluted net earnings (loss) per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.
(2) Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below.
Conference Call
The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its fourth quarter and full-year 2023 results.
To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.
This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
Consolidated Condensed Statements of Income (Loss) |
||||||||||||||||
(in thousands except per share amounts, unaudited) |
||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
Three Months Ended |
|
Year Ended |
||||||||||||
|
|
December 31, |
|
December 31, |
||||||||||||
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
||||||||
Net sales |
|
$ |
327,045 |
|
|
$ |
250,867 |
|
|
$ |
1,244,744 |
|
|
$ |
1,045,472 |
|
Cost of sales |
|
|
144,870 |
|
|
|
119,005 |
|
|
|
568,499 |
|
|
|
474,227 |
|
Gross profit |
|
|
182,175 |
|
|
|
131,862 |
|
|
|
676,245 |
|
|
|
571,245 |
|
% of sales |
|
|
55.7 |
% |
|
|
52.6 |
% |
|
|
54.3 |
% |
|
|
54.6 |
% |
Selling & administrative expense |
|
|
117,960 |
|
|
|
120,737 |
|
|
|
503,040 |
|
|
454,039 |
|
|
Research & development expense |
|
|
14,028 |
|
|
|
12,220 |
|
|
|
52,602 |
|
|
|
47,152 |
|
Income (loss) from operations |
|
|
50,187 |
|
|
|
(1,095 |
) |
|
|
120,603 |
|
|
|
70,054 |
|
% of sales |
|
|
15.3 |
% |
|
|
-0.4 |
% |
|
|
9.7 |
% |
|
|
6.7 |
% |
Interest expense |
|
|
9,505 |
|
|
|
9,443 |
|
|
|
39,775 |
|
|
|
28,905 |
|
Other expense |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
112,011 |
|
Income (loss) before income taxes |
|
|
40,682 |
|
|
|
(10,538 |
) |
|
|
80,828 |
|
|
|
(70,862 |
) |
Provision (benefit) for income taxes |
|
|
7,611 |
|
|
|
(37,122 |
) |
|
|
16,369 |
|
|
|
9,720 |
|
Net income (loss) |
|
$ |
33,071 |
|
|
$ |
26,584 |
|
|
$ |
64,459 |
|
|
$ |
(80,582 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Basic EPS |
|
$ |
1.08 |
|
|
$ |
0.87 |
|
|
$ |
2.10 |
|
|
$ |
(2.68 |
) |
Diluted EPS |
|
|
1.05 |
|
|
|
0.86 |
|
|
|
2.04 |
|
|
|
(2.68 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Basic shares |
|
|
30,759 |
|
|
|
30,484 |
|
|
|
30,668 |
|
|
|
30,040 |
|
Diluted shares |
|
|
31,502 |
|
|
|
30,931 |
|
|
|
31,548 |
|
|
|
30,040 |
|
Sales Summary |
|||||||||||||||||||||
(in millions, unaudited) |
|||||||||||||||||||||
|
|||||||||||||||||||||
Three Months Ended December 31, |
|||||||||||||||||||||
% Change |
|||||||||||||||||||||
Domestic |
International |
||||||||||||||||||||
|
2023 |
|
2022 |
As
|
Impact
|
Constant
|
|
As
|
As
|
Impact
|
Constant
|
||||||||||
Orthopedic Surgery |
$ |
136.5 |
$ |
115.2 |
18.5 |
% |
0.9 |
% |
19.4 |
% |
6.0 |
% |
27.8 |
% |
2.0 |
% |
29.8 |
% |
|||
General Surgery |
|
190.5 |
|
135.7 |
40.4 |
% |
1.3 |
% |
41.7 |
% |
47.6 |
% |
24.4 |
% |
3.4 |
% |
27.8 |
% |
|||
$ |
327.0 |
$ |
250.9 |
30.4 |
% |
1.1 |
% |
31.5 |
% |
33.3 |
% |
26.5 |
% |
2.5 |
% |
29.0 |
% |
||||
Single-use Products |
$ |
271.3 |
$ |
211.9 |
28.1 |
% |
1.1 |
% |
29.2 |
% |
33.1 |
% |
20.6 |
% |
2.6 |
% |
23.2 |
% |
|||
Capital Products |
|
55.7 |
|
39.0 |
42.9 |
% |
0.9 |
% |
43.8 |
% |
34.5 |
% |
49.3 |
% |
1.9 |
% |
51.2 |
% |
|||
$ |
327.0 |
$ |
250.9 |
30.4 |
% |
1.1 |
% |
31.5 |
% |
33.3 |
% |
26.5 |
% |
2.5 |
% |
29.0 |
% |
||||
Domestic |
$ |
190.3 |
$ |
142.8 |
33.3 |
% |
0.0 |
% |
33.3 |
% |
|||||||||||
International |
|
136.7 |
|
108.1 |
26.5 |
% |
2.5 |
% |
29.0 |
% |
|||||||||||
$ |
327.0 |
$ |
250.9 |
30.4 |
% |
1.1 |
% |
31.5 |
% |
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|||||||||||||||||||||
Year Ended December 31, |
|||||||||||||||||||||
% Change |
|||||||||||||||||||||
Domestic |
International |
||||||||||||||||||||
|
2023 |
|
2022 |
As
|
Impact
|
Constant
|
|
As
|
As
|
Impact
|
Constant
|
||||||||||
Orthopedic Surgery |
$ |
533.1 |
$ |
461.5 |
15.5 |
% |
2.2 |
% |
17.7 |
% |
15.2 |
% |
15.7 |
% |
3.5 |
% |
19.2 |
% |
|||
General Surgery |
|
711.6 |
|
584.0 |
21.9 |
% |
1.5 |
% |
23.4 |
% |
23.4 |
% |
18.4 |
% |
5.1 |
% |
23.5 |
% |
|||
$ |
1,244.7 |
$ |
1,045.5 |
19.1 |
% |
1.8 |
% |
20.9 |
% |
20.9 |
% |
16.7 |
% |
4.2 |
% |
20.9 |
% |
||||
Single-use Products |
$ |
1,038.5 |
$ |
874.9 |
18.7 |
% |
1.8 |
% |
20.5 |
% |
21.3 |
% |
15.2 |
% |
4.3 |
% |
19.5 |
% |
|||
Capital Products |
|
206.2 |
|
170.6 |
20.9 |
% |
1.9 |
% |
22.8 |
% |
18.5 |
% |
22.8 |
% |
3.6 |
% |
26.4 |
% |
|||
$ |
1,244.7 |
$ |
1,045.5 |
19.1 |
% |
1.8 |
% |
20.9 |
% |
20.9 |
% |
16.7 |
% |
4.2 |
% |
20.9 |
% |
||||
Domestic |
$ |
700.1 |
$ |
579.0 |
20.9 |
% |
0.0 |
% |
20.9 |
% |
|||||||||||
International |
|
544.6 |
|
466.5 |
16.7 |
% |
4.2 |
% |
20.9 |
% |
|||||||||||
$ |
1,244.7 |
$ |
1,045.5 |
19.1 |
% |
1.8 |
% |
20.9 |
% |
||||||||||||
|
|||||||||||||||||||||
Reconciliation of Reported Net Income to Adjusted Net Income |
||||||||||||||||||||||||||||||
(in thousands, except per share amounts, unaudited) |
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Three Months Ended December 31, 2023 |
|
|||||||||||||||||||||||||||||
Gross Profit |
Selling &
|
Operating
|
Interest
|
Tax
|
Effective
|
Net Income |
Basic EPS |
Adjustments |
Diluted EPS |
|
||||||||||||||||||||
As reported |
$ |
182,175 |
|
$ |
117,960 |
|
$ |
50,187 |
|
$ |
9,505 |
|
$ |
7,611 |
|
18.7 |
% |
$ |
33,071 |
|
$ |
- |
$ |
33,071 |
|
|
||||
% of sales |
|
55.7 |
% |
|
36.1 |
% |
|
15.3 |
% |
|
||||||||||||||||||||
EPS |
$ |
1.08 |
$ |
1.05 |
|
|
||||||||||||||||||||||||
Shares |
|
30,759 |
|
743 |
|
31,502 |
|
|
||||||||||||||||||||||
Acquisition and integration costs(1) |
|
2,154 |
|
|
- |
|
|
2,154 |
|
|
- |
|
|
(162 |
) |
|
2,316 |
|
|
|||||||||||
Contingent consideration fair value adjustment(2) |
|
- |
|
|
9,370 |
|
|
(9,370 |
) |
|
- |
|
|
703 |
|
|
|
(10,073 |
) |
|
||||||||||
$ |
184,329 |
|
$ |
127,330 |
|
$ |
42,971 |
|
$ |
9,505 |
|
$ |
8,152 |
|
|
$ |
25,314 |
|
|
|||||||||||
Adjusted gross profit % |
|
56.4 |
% |
|
||||||||||||||||||||||||||
Amortization(3) |
$ |
1,500 |
|
|
(7,295 |
) |
|
8,795 |
|
|
(1,500 |
) |
|
2,458 |
|
|
7,837 |
|
|
|||||||||||
As adjusted |
$ |
120,035 |
|
$ |
51,766 |
|
$ |
8,005 |
|
$ |
10,610 |
|
24.2 |
% |
$ |
33,151 |
|
$ |
- |
$ |
33,151 |
|
|
|||||||
% of sales |
|
|
36.7 |
% |
|
15.8 |
% |
|
||||||||||||||||||||||
Adjusted diluted EPS |
$ |
1.06 |
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Shares |
|
30,759 |
|
743 |
|
31,502 |
|
|
||||||||||||||||||||||
Convertible note hedges(4) |
|
(110 |
) |
|
||||||||||||||||||||||||||
Adjusted diluted shares |
|
31,392 |
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
Three Months Ended December 31, 2022 |
|
|
|
|
|||||||||||||||||||||||||
Gross Profit |
Selling &
|
Operating
|
Interest
|
Tax
|
Effective
|
Net Income |
Basic EPS |
Adjustments(7) |
Diluted EPS |
|
||||||||||||||||||||
As reported |
$ |
131,862 |
|
$ |
120,737 |
|
$ |
(1,095 |
) |
$ |
9,443 |
|
$ |
(37,122 |
) |
352.3 |
% |
$ |
26,584 |
|
$ |
- |
$ |
26,584 |
|
|
||||
% of sales |
|
52.6 |
% |
|
48.1 |
% |
|
-0.4 |
% |
|
||||||||||||||||||||
EPS |
$ |
0.87 |
|
$ |
0.86 |
|
|
|||||||||||||||||||||||
Shares |
|
30,484 |
|
447 |
|
30,931 |
|
|
||||||||||||||||||||||
Acquisition and integration costs(1) |
|
2,096 |
|
|
(3,757 |
) |
|
5,853 |
|
|
- |
|
|
12,873 |
|
|
|
(7,020 |
) |
|
|
|
|
|||||||
Restructuring and related costs(5) |
|
1,955 |
|
|
(786 |
) |
|
2,741 |
|
|
- |
|
|
6,029 |
|
|
|
(3,288 |
) |
|
|
|
|
|||||||
Software implementation costs(6) |
|
- |
|
|
(6,769 |
) |
|
6,769 |
|
|
- |
|
|
14,889 |
|
|
|
(8,120 |
) |
|
|
|
|
|||||||
Contingent consideration fair value adjustment(2) |
|
- |
|
|
(2,518 |
) |
|
2,518 |
|
|
- |
|
|
5,538 |
|
|
|
(3,020 |
) |
|
||||||||||
$ |
135,913 |
|
$ |
106,907 |
|
$ |
16,786 |
|
$ |
9,443 |
|
$ |
2,207 |
|
|
$ |
5,136 |
|
|
|||||||||||
Adjusted gross profit % |
|
54.2 |
% |
|
||||||||||||||||||||||||||
Amortization(3) |
$ |
1,500 |
|
|
(7,228 |
) |
|
8,728 |
|
|
(1,506 |
) |
|
2,446 |
|
|
7,788 |
|
|
|||||||||||
As adjusted |
$ |
99,679 |
|
$ |
25,514 |
|
$ |
7,937 |
|
$ |
4,653 |
|
26.5 |
% |
$ |
12,924 |
|
$ |
- |
$ |
12,924 |
|
|
|||||||
% of sales |
|
39.7 |
% |
|
10.2 |
% |
|
|||||||||||||||||||||||
Adjusted diluted EPS |
$ |
0.42 |
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Shares |
|
30,484 |
|
447 |
|
30,931 |
|
|
||||||||||||||||||||||
Convertible note hedges(4) |
|
- |
|
|
||||||||||||||||||||||||||
Adjusted diluted shares |
|
30,931 |
|
|
||||||||||||||||||||||||||
(1) In 2023, the Company incurred charges related to the amortization of inventory step-up to fair value associated with the acquisition of In2Bones Global, Inc. In 2022, the Company incurred charges related to the amortization of inventory step-up to fair value and consulting fees, legal fees, and other integration costs associated with the acquisitions of In2Bones Global, Inc. and Biorez, Inc. |
(2) In 2023 and 2022, the Company incurred income/(expense) related to the fair value adjustments of contingent consideration. |
(3) Includes amortization of intangible assets and deferred financing fees. |
(4) Non-GAAP adjusted dilutive weighted average shares outstanding exclude dilution that is expected to be offset by the Company’s convertible notes hedge transactions. |
(5) In 2022, the Company incurred consulting fees related to an operational cost improvement initiative and severance related to the elimination of certain positions. |
(6) In 2022, the Company incurred incremental freight, professional fees and other costs related to the implementation of a warehouse management software. |
(7) The Company adopted ASU 2020-06, effective January 1, 2022. As a result of the adoption, the Company is required to compute diluted EPS using the if-converted method. Under the if-converted method, the numerator is adjusted for interest expense applicable to its convertible notes (net of tax) and the denominator includes additional common shares assuming conversion premium and principal portion of the notes (when permitted or required) are settled in shares. Subsequent to June 6, 2022, the Company is required to settle the principal value of its convertible notes in cash.
|
Reconciliation of Reported Net Income (Loss) to Adjusted Net Income |
|||||||||||||||||||||||||||||||||
(in thousands, except per share amounts, unaudited) |
|||||||||||||||||||||||||||||||||
Year Ended December 31, 2023 |
|
||||||||||||||||||||||||||||||||
Gross
|
Selling &
|
Operating
|
Interest
|
Other
|
Tax
|
Effective
|
Net
|
Basic
|
Adjustments |
Diluted EPS |
|
||||||||||||||||||||||
As reported |
$ |
676,245 |
|
$ |
503,040 |
|
$ |
120,603 |
|
$ |
39,775 |
|
$ |
- |
|
$ |
16,369 |
|
20.3 |
% |
$ |
64,459 |
|
$ |
- |
$ |
64,459 |
|
|
||||
% of sales |
|
54.3 |
% |
|
40.4 |
% |
|
9.7 |
% |
|
|||||||||||||||||||||||
EPS |
$ |
2.10 |
|
$ |
2.04 |
|
|
||||||||||||||||||||||||||
Shares |
|
30,668 |
|
|
880 |
|
31,548 |
|
|
||||||||||||||||||||||||
Acquisition and integration costs(1) |
|
8,617 |
|
|
(752 |
) |
|
9,369 |
|
|
- |
|
|
- |
|
|
1,207 |
|
|
8,162 |
|
|
|||||||||||
Termination of distributor agreements(2) |
|
- |
|
|
(2,098 |
) |
|
2,098 |
|
|
- |
|
|
- |
|
|
417 |
|
|
1,681 |
|
|
|||||||||||
Restructuring and related costs(3) |
|
2,035 |
|
|
(1,578 |
) |
|
3,613 |
|
|
- |
|
|
- |
|
|
930 |
|
|
|
2,683 |
|
|
|
|
|
|||||||
Software implementation costs(4) |
|
- |
|
|
(6,056 |
) |
|
6,056 |
|
|
- |
|
|
- |
|
|
1,453 |
|
|
4,603 |
|
|
|||||||||||
Contingent consideration fair value adjustment(5) |
|
- |
|
|
2,421 |
|
|
(2,421 |
) |
|
- |
|
|
- |
|
|
2,037 |
|
|
(4,458 |
) |
|
|||||||||||
$ |
686,897 |
|
$ |
494,977 |
|
$ |
139,318 |
|
$ |
39,775 |
|
$ |
- |
|
$ |
22,413 |
|
|
$ |
77,130 |
|
|
|||||||||||
Adjusted gross profit % |
|
55.2 |
% |
|
|||||||||||||||||||||||||||||
Amortization(6) |
$ |
6,000 |
|
|
(29,068 |
) |
|
35,068 |
|
|
(6,058 |
) |
|
- |
|
|
9,969 |
|
|
|
31,157 |
|
|
|
|
||||||||
As adjusted |
$ |
465,909 |
|
$ |
174,386 |
|
$ |
33,717 |
|
$ |
- |
|
$ |
32,382 |
|
23.0 |
% |
$ |
108,287 |
|
$ |
- |
$ |
108,287 |
|
|
|||||||
% of sales |
|
37.4 |
% |
|
14.0 |
% |
|
||||||||||||||||||||||||||
Adjusted diluted EPS |
$ |
3.45 |
|
|
|||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Shares |
|
30,668 |
|
|
880 |
|
31,548 |
|
|
||||||||||||||||||||||||
Convertible note hedges(7) |
|
(142 |
) |
|
|||||||||||||||||||||||||||||
Adjusted diluted shares |
|
31,406 |
|
|
|||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
|
Year Ended December 31, 2022 |
|
|||||||||||||||||||||||||||||||
Gross
|
Selling &
|
Operating
|
Interest
|
Other
|
Tax
|
Effective
|
Net
|
Basic
|
Adjustments(12) |
Diluted EPS |
|
||||||||||||||||||||||
As reported |
$ |
571,245 |
|
$ |
454,039 |
|
$ |
70,054 |
|
$ |
28,905 |
|
$ |
112,011 |
|
$ |
9,720 |
|
-13.7 |
% |
$ |
(80,582 |
) |
$ |
- |
$ |
(80,582 |
) |
|
||||
% of sales |
|
54.6 |
% |
|
43.4 |
% |
|
6.7 |
% |
|
|||||||||||||||||||||||
EPS |
$ |
(2.68 |
) |
|
$ |
(2.68 |
) |
|
|||||||||||||||||||||||||
Shares |
|
30,040 |
|
|
- |
|
30,040 |
|
|
||||||||||||||||||||||||
Acquisition and integration costs(1) |
|
4,540 |
|
|
(10,063 |
) |
|
14,603 |
|
|
- |
|
|
- |
|
|
46,965 |
|
|
(32,362 |
) |
|
|||||||||||
Legal matters(8) |
|
- |
|
|
(775 |
) |
|
775 |
|
|
- |
|
|
- |
|
|
(462 |
) |
|
1,237 |
|
|
|||||||||||
Restructuring and related costs(3) |
|
1,955 |
|
|
(786 |
) |
|
2,741 |
|
|
- |
|
|
- |
|
|
6,029 |
|
|
|
(3,288 |
) |
|
|
|
|
|||||||
Software implementation costs(4) |
|
- |
|
|
(6,769 |
) |
|
6,769 |
|
|
- |
|
|
- |
|
|
14,889 |
|
|
|
(8,120 |
) |
|
|
|
|
|||||||
Contingent consideration fair value adjustment(5) |
|
- |
|
|
(2,518 |
) |
|
2,518 |
|
|
- |
|
|
- |
|
|
5,538 |
|
|
|
(3,020 |
) |
|
|
|
|
|||||||
Convertible notes premium on extinguishment(9) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(103,125 |
) |
|
(61,521 |
) |
|
164,646 |
|
|
|||||||||||
Change in fair value of convertible notes hedges upon settlement(10) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(5,460 |
) |
|
(3,257 |
) |
|
8,717 |
|
|
|||||||||||
Loss on early extinguishment of debt(11) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(3,426 |
) |
|
(2,044 |
) |
|
5,470 |
|
|
|||||||||||
$ |
577,740 |
|
$ |
433,128 |
|
$ |
97,460 |
|
$ |
28,905 |
|
$ |
- |
|
$ |
15,857 |
|
|
$ |
52,698 |
|
|
|||||||||||
Adjusted gross profit % |
|
55.3 |
% |
|
|
|
|||||||||||||||||||||||||||
Amortization(6) |
$ |
6,000 |
|
|
(27,791 |
) |
|
33,791 |
|
|
(4,910 |
) |
|
- |
|
|
9,381 |
|
|
|
29,320 |
|
|
|
|
||||||||
As adjusted |
$ |
405,337 |
|
$ |
131,251 |
|
$ |
23,995 |
|
$ |
- |
|
$ |
25,238 |
|
23.5 |
% |
$ |
82,018 |
|
$ |
2,978 |
$ |
84,996 |
|
|
|||||||
% of sales |
|
38.8 |
% |
|
12.6 |
% |
|
||||||||||||||||||||||||||
Adjusted diluted EPS |
$ |
2.65 |
|
|
|||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Shares |
|
30,040 |
|
|
2,656 |
|
32,696 |
|
|
||||||||||||||||||||||||
Convertible note hedges(7) |
|
(578 |
) |
|
|||||||||||||||||||||||||||||
Adjusted diluted shares |
|
32,118 |
|
|
|||||||||||||||||||||||||||||
(1) In 2023, the Company incurred charges related to the amortization of inventory step-up to fair value associated with the acquisition of In2Bones Global, Inc., and integration costs and professional fees associated with the acquisitions of In2Bones Global, Inc. and Biorez, Inc. In 2022, the Company incurred charges related to the amortization of inventory step-up to fair value and consulting fees, legal fees, and other integration costs associated with the acquisition of In2Bones Global, Inc. and Biorez, Inc. |
(2) In 2023, the Company incurred costs related to the termination of distributor agreements. |
(3) In 2023 and 2022, the Company incurred consulting fees related to an operational cost improvement initiative and severance related to the elimination of certain positions. |
(4) In 2023 and 2022, the Company incurred additional freight, labor and travel costs as well as professional fees related to the implementation of a warehouse management software. |
(5) In 2023 and 2022, the Company incurred income/(expense) related to the fair value adjustments of contingent consideration. |
(6) Includes amortization of intangible assets and deferred financing fees. |
(7) Non-GAAP adjusted dilutive weighted average shares outstanding exclude dilution that is expected to be offset by the Company’s convertible notes hedge transactions. |
(8) In 2022, the Company incurred costs related to a legal settlement. |
(9) In 2022, the Company incurred costs related to the conversion premium on the repurchase and extinguishment of |
(10) In 2022, the Company incurred costs related to the settlement of convertible notes hedge transactions associated with the repurchase and extinguishment of |
(11) In 2022, the Company incurred costs related to the write-off of deferred financing fees associated with the repurchase and extinguishment of |
(12) The Company adopted ASU 2020-06, effective January 1, 2022. As a result of the adoption, the Company is required to compute diluted EPS using the if-converted method. Under the if-converted method, the numerator is adjusted for interest expense applicable to its convertible notes (net of tax) and the denominator includes additional common shares assuming conversion premium and principal portion of the notes (when permitted or required) are settled in shares. Subsequent to June 6, 2022, the Company is required to settle the principal value of its convertible notes in cash. Adjustments in 2022 are applicable on a non-GAAP basis only since GAAP results are in a loss position and therefore exclude dilutive potential shares. |
Reconciliation of Reported Net Income (Loss) to EBITDA & Adjusted EBITDA |
|||||||||||||||
(in thousands, unaudited) |
|||||||||||||||
|
|
|
|
|
|||||||||||
|
Three Months Ended |
|
Year Ended |
||||||||||||
|
December 31, |
|
December 31, |
||||||||||||
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
|
|
|
|
||||||||
Net income (loss) |
$ |
33,071 |
|
|
$ |
26,584 |
|
|
$ |
64,459 |
|
|
$ |
(80,582 |
) |
Provision (benefit) for income taxes |
|
7,611 |
|
|
|
(37,122 |
) |
|
|
16,369 |
|
|
|
9,720 |
|
Interest expense |
|
9,505 |
|
|
|
9,443 |
|
|
|
39,775 |
|
|
|
28,905 |
|
Depreciation |
|
4,052 |
|
|
|
4,026 |
|
|
|
16,200 |
|
|
|
16,055 |
|
Amortization |
|
13,950 |
|
|
|
13,709 |
|
|
|
55,674 |
|
|
|
53,464 |
|
EBITDA |
$ |
68,189 |
|
|
$ |
16,640 |
|
|
$ |
192,477 |
|
|
$ |
27,562 |
|
|
|
|
|
|
|
|
|
||||||||
Stock based compensation |
|
5,923 |
|
|
|
5,758 |
|
|
|
24,257 |
|
|
|
21,729 |
|
Acquisition and integration costs |
|
2,154 |
|
|
|
5,853 |
|
|
|
9,369 |
|
|
|
14,603 |
|
Contingent consideration fair value adjustment |
|
(9,370 |
) |
|
|
2,518 |
|
|
|
(2,421 |
) |
|
|
2,518 |
|
Termination of distributor agreements |
|
- |
|
|
|
- |
|
|
|
2,098 |
|
|
|
- |
|
Restructuring and related costs |
|
- |
|
|
|
2,741 |
|
|
|
3,613 |
|
|
|
2,741 |
|
Software implementation costs |
|
- |
|
|
|
6,769 |
|
|
|
6,056 |
|
|
|
6,769 |
|
Legal matters |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
775 |
|
Convertible notes premium on extinguishment |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
103,125 |
|
Change in fair value of convertible notes hedges upon settlement |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
5,460 |
|
Loss on early extinguishment of debt |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
3,426 |
|
Adjusted EBITDA |
$ |
66,896 |
|
|
$ |
40,279 |
|
|
$ |
235,449 |
|
|
$ |
188,708 |
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
||||||||
EBITDA Margin |
|
|
|
|
|
|
|
||||||||
EBITDA |
|
20.9 |
% |
|
|
6.6 |
% |
|
|
15.5 |
% |
|
|
2.6 |
% |
Adjusted EBITDA |
|
20.5 |
% |
|
16.1 |
% |
|
|
18.9 |
% |
|
18.1 |
% |
||
About CONMED Corporation
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.
Forward-Looking Statements
This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2022, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures
The Company supplements the reporting of its financial information determined under generally accepted accounting principles in
Net sales on a constant currency basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.
Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, operating income (loss), interest expense, other expense, income tax expense (benefit), effective income tax rate, net income (loss), diluted shares and diluted net earnings (loss) per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.
We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated condensed statements of income.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131915000/en/
CONMED Corporation
Todd W. Garner
Chief Financial Officer
727-214-2975
ToddGarner@conmed.com
Source: CONMED Corporation
FAQ
What is the ticker symbol for CONMED Corporation?
What was the percentage increase in sales for the fourth quarter of 2023?
How much did domestic revenue increase by in the fourth quarter of 2023?
By how much did adjusted diluted net earnings per share increase in the fourth quarter of 2023?
What is the projected year-over-year revenue growth for 2024?
What is the expected growth in adjusted diluted net earnings per share for 2024?
